In addition, EGFR-TKI,BCR-ABL TKIs, mTOR inhibitors and anti-angiogenesis treatments have not received approval for SCLC due to a lack of clinical efficiency9, 10. This evidence concerns the gene MTOR and small cell lung carcinoma.